Department of Health & Human Services Centers for Medicare & Medicaid Services 61 Forsyth St., Suite 4T20 Atlanta, Georgia 30303-8909



March 22, 2010

Craigan Gray, MD, MBA, JD
Director
Division of Medical Assistance
North Carolina Department of Health and Human Services
2501 Mail Service Center
Raleigh, North Carolina 27699-2501

Attention: Teresa Smith

RE: North Carolina Title XIX State Plan Amendment, Transmittal #09-028

Dear Dr. Gray:

This is a follow up to the approval letter that you should have received from Mr. Larry Reed, Director, Division of Pharmacy, and Centers for Medicare & Medicaid Services, dated March 16, 2010. Enclosed is a copy of the approval letter, the signed form HCFA-179 and the approved plan page.

The effective date of this amendment is October 1, 2009.

Sincerely,

//s//

Jackie Glaze Acting Associate Regional Administrator Division of Medicaid & Children's Health Operations

Enclosures

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-14-26 Baltimore, Maryland 21244-1850



Centers for Medicaid & State Operations

Disabled and Elderly Health Programs Group

March 16, 2010

Lanier M. Cansler Office of the Secretary North Carolina Department of Health and Human Services 2001 Mail Service Center Raleigh, North Carolina 27699-2001

Dear Mr. Cansler:

We have reviewed North Carolina State Plan Amendment (SPA) 09-028, Prescribed Drugs, including the additional information provided by the state at the request of CMS. This amendment authorizes the state to enter into the First Health National Medicaid Pooling Initiative (NMPI) Multi-State Pooling Supplemental Rebate Agreement (SRA). We believe that the SPA and SRA are designed to increase the efficiency and economy of the Medicaid program and benefit the Medicaid population. We are pleased to inform you that the amendment is approved, effective October 1, 2009.

Please note that the approval of SPA 09-028 extends only to the SRA, amendments, and exhibits that were submitted to the Centers for Medicare & Medicaid Services (SRA) on December 31, 2010. If changes are subsequently made to the supplemental drug rebate agreements, amendments, or exhibits, any such documents should be submitted to CMS for review and authorization.

A copy of the CMS-179 form, as well as the pages approved for incorporation into the North Carolina's state plan will be forwarded by the Atlanta Regional Office. If you have any further questions or require additional information, please contact Kim Howell at (410) 786-6762.

Sincerely,

/s/

Larry Reed Director Division of Pharmacy

cc: Mary Kaye Justis, Acting ARA Atlanta Regional Office Cheryl Brimage, Atlanta Regional Office

12.a. <u>Prescribed Drugs (continued)</u>

- (4) DESI drugs and any identical, similar or related products or combinations of these products are not covered.
- (5) Supplemental Medicaid Drug Rebate Agreements

A rebate agreement between the State and a drug manufacturer for drugs provided to the Medicaid population, submitted to CMS on December 30, 2009 and entitled, "State of North Carolina First Health Services National Medicaid Pooling Initiative (NMPI)," has been authorized by CMS.

The State assures compliance with Section 1927 of the Social Security Act. Drugs of federal rebate participating manufacturers are covered. Policies for the supplemental rebate program for Medicaid beneficiaries are as follows:

- a) Supplemental rebates received by the State in excess of those required under the national drug rebate agreement will be shared with the Federal government on the same percentage basis as applied under the national rebate agreement.
- b) Supplemental rebates are for the Medicaid population only.
- c) The State will be negotiating supplemental rebates in addition to the federal rebates provided for in Title XIX. Rebate agreements between the State and a pharmaceutical manufacturer will be separate from the federal rebates.
- d) All drugs covered by the program, irrespective of placement on the recommended drug list, will comply with the provisions of the national drug rebate agreement.
- e) The State is in compliance with reporting requirements for utilization and restrictions to coverage. Pharmaceutical manufacturers may audit utilization data. The unit rebate amount is confidential and cannot be disclosed for purposes other than rebate invoicing and verification.
- f) Participation in the First Health Services National Medicaid Pooling Initiative (NMPI) will not limit the State's ability to negotiate state-specific supplemental rebate agreements for specific drug classes that are not part of the NMPI. These agreements must be authorized by CMS.
- g) Participation in the NMPI is voluntary for manufacturers.

TN No.: <u>09-028</u> Supersedes

TN. No.: NEW

Approval Date: 03-15-10 Effective Date: 10/01/09